2026 ICD-10-CM Diagnosis Code T47.1X2SPoisoning by other antacids and anti-gastric-secretion drugs, intentional self-harm, sequela

ICD-10-CM CodesS00–T88T36-T50T47

ICD-10-CM T47.1X2S
CMSSource: CMS FY 2026 ICD-10-CM dataset · Effective Oct 1, 2025 – Sep 30, 2026

T47.1X2S is a billable ICD-10-CM diagnosis code for poisoning by other antacids and anti-gastric-secretion drugs, intentional self-harm, sequela. The 7th character S marks it as a sequela code, which reports a problem that remains after the original condition has resolved. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 922 through 923. The code is exempt from POA reporting. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Mental and substance use disorders; sequela; and Poisoning/toxic effect/adverse effects/underdosing, sequela.

Code Identity

ICD-10-CM Code
T47.1X2S
Billable Status
Yes — Valid for Submission
Code Describes
Poisoning by other antacids and anti-gastric-secretion drugs, intentional self-harm, sequela
Short Description
Poisn by oth antacids & anti-gstrc-sec drugs, slf-hrm, sqla
Parent Code
Poisoning by other antacids and anti-gastric-secretion drugs, intentional self-harm

Code Classification

ChapterS00–T88Injury, poisoning and certain other consequences of external causes
SectionT36-T50Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances
CategoryT47Poisoning by, adverse effect of and underdosing of agents primarily affecting the gastrointestinal system
This CodeT47.1X2SPoisoning by other antacids and anti-gastric-secretion drugs, intentional self-harm, sequela

Present on Admission (POA)Billing

T47.1X2S is exempt from POA reporting on inpatient claims to general acute care hospitals. Review other POA exempt codes.

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Aluminum hydroxide overdose
  • Antacid overdose
  • Anticholinergic drug overdose
  • Carbenoxolone overdose
  • Carbenoxolone poisoning
  • Intentional aluminum hydroxide overdose
  • Intentional aluminum hydroxide poisoning
  • Intentional carbenoxolone overdose
  • Intentional carbenoxolone poisoning
  • Intentional lansoprazole overdose
  • Intentional lansoprazole poisoning
  • Intentional magnesium trisilicate overdose
  • Intentional magnesium trisilicate poisoning
  • Intentional misoprostol overdose
  • Intentional misoprostol poisoning
  • Intentional omeprazole overdose
  • Intentional omeprazole poisoning
  • Intentional pirenzepine overdose
  • Intentional pirenzepine poisoning
  • Intentional prostaglandin overdose
  • Intentional prostaglandin poisoning
  • Intentional sucralfate overdose
  • Intentional sucralfate poisoning
  • Lansoprazole overdose
  • Lansoprazole poisoning
  • Magnesium trisilicate overdose
  • Misoprostol overdose
  • Misoprostol poisoning
  • Omeprazole overdose
  • Omeprazole poisoning
  • Pirenzepine overdose
  • Pirenzepine poisoning
  • Poisoning by aluminum hydroxide
  • Poisoning by magnesium trisilicate
  • Prostaglandin overdose
  • Proton pump inhibitor overdose
  • Sucralfate overdose
  • Sucralfate poisoning

Coding GuidelinesGuidance

When coding a poisoning or reaction to the improper use of a medication (e.g., overdose, wrong substance given or taken in error, wrong route of administration), first assign the appropriate code from categories T36-T50. The poisoning codes have an associated intent as their 5th or 6th character (accidental, intentional self-harm, assault and undetermined). If the intent of the poisoning is unknown or unspecified, code the intent as accidental intent. The undetermined intent is only for use if the documentation in the record specifies that the intent cannot be determined. Use additional code(s) for all manifestations of poisonings.

The appropriate 7th character is to be added to each code from block Poisoning by, adverse effect of and underdosing of agents primarily affecting the gastrointestinal system (T47). Use the following options for the applicable episode of care:

  • A - initial encounter
  • D - subsequent encounter
  • S - sequela

Source: ICD-10-CM Official Guidelines for Coding and Reporting, FY 2026, published by CMS and the National Center for Health Statistics.

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR MBD034
Mental and substance use disorders; sequela
Default principal diagnosis: inpatient Yes · outpatient Yes
CCSR INJ075
Poisoning/toxic effect/adverse effects/underdosing, sequela
Default principal diagnosis: inpatient No · outpatient No

Clinical InformationClinical

  • Burimamide

    an antagonist of histamine that appears to block both h2 and h3 histamine receptors. it has been used in the treatment of ulcers.
  • Carbenoxolone

    an agent derived from licorice root. it is used for the treatment of digestive tract ulcers, especially in the stomach. antidiuretic side effects are frequent, but otherwise the drug is low in toxicity.
  • Enprostil

    a synthetic pge2 analog that has an inhibitory effect on gastric acid secretion, a mucoprotective effect, and a postprandial lowering effect on gastrin. it has been shown to be efficient and safe in the treatment of gastroduodenal ulcers.
  • Metiamide

    a histamine h2 receptor antagonist that is used as an anti-ulcer agent.
  • Misoprostol

    a synthetic analog of natural prostaglandin e1. it produces a dose-related inhibition of gastric acid and pepsin secretion, and enhances mucosal resistance to injury. it is an effective anti-ulcer agent and also has oxytocic properties.
  • Omeprazole

    a 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of stomach ulcers and zollinger-ellison syndrome. the drug inhibits an h(+)-k(+)-exchanging atpase which is found in gastric parietal cells.
  • Pirenzepine

    an antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. it promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. it also potentiates the effect of other antiulcer agents such as cimetidine and ranitidine. it is generally well tolerated by patients.
  • Proglumide

    a drug that exerts an inhibitory effect on gastric secretion and reduces gastrointestinal motility. it is used clinically in the drug therapy of gastrointestinal ulcers.
  • Simethicone

    a poly(dimethylsiloxane) which is a polymer of 200-350 units of dimethylsiloxane, along with added silica gel. it is used as an antiflatulent, surfactant, and ointment base.
  • Sucralfate

    a basic aluminum complex of sulfated sucrose.

Table of Drugs and ChemicalsClinical

Substances in the Table of Drugs and Chemicals that reference this code family. Always confirm in the Tabular List before coding.

SubstanceAccidentalSelf-harmAssaultUndeter­minedAdverse
Effect
Under­dosing
Alexitol sodiumT47.1X1T47.1X2T47.1X3T47.1X4T47.1X5T47.1X6
AlgeldrateT47.1X1T47.1X2T47.1X3T47.1X4T47.1X5T47.1X6
AlmagateT47.1X1T47.1X2T47.1X3T47.1X4T47.1X5T47.1X6
AlmasilateT47.1X1T47.1X2T47.1X3T47.1X4T47.1X5T47.1X6
AloglutamolT47.1X1T47.1X2T47.1X3T47.1X4T47.1X5T47.1X6
Antacid NECT47.1X1T47.1X2T47.1X3T47.1X4T47.1X5T47.1X6
Anti-gastric-secretion drug NECT47.1X1T47.1X2T47.1X3T47.1X4T47.1X5T47.1X6
BenexateT47.1X1T47.1X2T47.1X3T47.1X4T47.1X5T47.1X6
BurimamideT47.1X1T47.1X2T47.1X3T47.1X4T47.1X5T47.1X6
CarbenoxoloneT47.1X1T47.1X2T47.1X3T47.1X4T47.1X5T47.1X6
CetraxateT47.1X1T47.1X2T47.1X3T47.1X4T47.1X5T47.1X6
Chalk, precipitatedT47.1X1T47.1X2T47.1X3T47.1X4T47.1X5T47.1X6
Dihydroxyaluminum aminoacetateT47.1X1T47.1X2T47.1X3T47.1X4T47.1X5T47.1X6
Dihydroxyaluminum sodium carbonateT47.1X1T47.1X2T47.1X3T47.1X4T47.1X5T47.1X6
DimethiconeT47.1X1T47.1X2T47.1X3T47.1X4T47.1X5T47.1X6
DimeticoneT47.1X1T47.1X2T47.1X3T47.1X4T47.1X5T47.1X6
EnprostilT47.1X1T47.1X2T47.1X3T47.1X4T47.1X5T47.1X6
HydrotalciteT47.1X1T47.1X2T47.1X3T47.1X4T47.1X5T47.1X6
MagaldrateT47.1X1T47.1X2T47.1X3T47.1X4T47.1X5T47.1X6
Magnesia magmaT47.1X1T47.1X2T47.1X3T47.1X4T47.1X5T47.1X6
MethylpolysiloxaneT47.1X1T47.1X2T47.1X3T47.1X4T47.1X5T47.1X6
MetiamideT47.1X1T47.1X2T47.1X3T47.1X4T47.1X5T47.1X6
Milk of magnesiaT47.1X1T47.1X2T47.1X3T47.1X4T47.1X5T47.1X6
MisoprostolT47.1X1T47.1X2T47.1X3T47.1X4T47.1X5T47.1X6
OmeprazoleT47.1X1T47.1X2T47.1X3T47.1X4T47.1X5T47.1X6
OrnoprostilT47.1X1T47.1X2T47.1X3T47.1X4T47.1X5T47.1X6
PepstatinT47.1X1T47.1X2T47.1X3T47.1X4T47.1X5T47.1X6
PirenzepineT47.1X1T47.1X2T47.1X3T47.1X4T47.1X5T47.1X6
ProglumideT47.1X1T47.1X2T47.1X3T47.1X4T47.1X5T47.1X6
RolaidsT47.1X1T47.1X2T47.1X3T47.1X4T47.1X5T47.1X6
RosaprostolT47.1X1T47.1X2T47.1X3T47.1X4T47.1X5T47.1X6
SimaldrateT47.1X1T47.1X2T47.1X3T47.1X4T47.1X5T47.1X6
SimethiconeT47.1X1T47.1X2T47.1X3T47.1X4T47.1X5T47.1X6
SucralfateT47.1X1T47.1X2T47.1X3T47.1X4T47.1X5T47.1X6
SulglicotideT47.1X1T47.1X2T47.1X3T47.1X4T47.1X5T47.1X6

Patient EducationClinical

Poisoning

A poison is any substance that is harmful to your body. You might swallow it, inhale it, inject it, or absorb it through your skin. Any substance can be poisonous if too much is taken. Poisons can include:

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert T47.1X2S to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
909.0 Late eff drug poisoning
ApproximateCombination The match is approximate, and more than one code can be needed to describe the source diagnosis. Confirm with contextual judgment.
ICD-9-CM
E959 Late eff of self-injury
ApproximateCombination The match is approximate, and more than one code can be needed to describe the source diagnosis. Confirm with contextual judgment.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2025No changes
FY 2026CurrentCurrent code set, no changesEffective October 1, 2025 through September 30, 2026.

Questions About T47.1X2SOverview

Is T47.1X2S a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report poisoning by other antacids and anti-gastric-secretion drugs, intentional self-harm, sequela on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

What does the 7th character S in T47.1X2S mean?

The final character S makes this a sequela code: it reports a lingering problem that remains after the poisoning by other antacids and anti-gastric-secretion drugs, intentional self-harm itself has resolved, not the original event.

What MS-DRG does T47.1X2S group to?

When poisoning by other antacids and anti-gastric-secretion drugs, intentional self-harm, sequela is the principal diagnosis on an inpatient stay, it groups to MS-DRG 922, 923, with relative weights from 1.0177 to 1.7494 depending on complications. Higher weights mean higher Medicare reimbursement.

Is T47.1X2S exempt from POA reporting?

Yes. CMS lists this code among those exempt from present on admission reporting, so hospitals do not assign a POA indicator for poisoning by other antacids and anti-gastric-secretion drugs, intentional self-harm, sequela on inpatient claims.

What is the ICD-9 equivalent of T47.1X2S?

Under the General Equivalence Mappings, poisoning by other antacids and anti-gastric-secretion drugs, intentional self-harm, sequela converts to ICD-9-CM 909.0 (late eff drug poisoning) and E959 (late eff of self-injury). The mapping is approximate, so confirm the match fits the documentation.

Footnotes

[1] Not chronic - A diagnosis code that does not fit the criteria for chronic condition (duration, ongoing medical treatment, and limitations) is considered not chronic. Some codes designated as not chronic are acute conditions. Other diagnosis codes that indicate a possible chronic condition, but for which the duration of the illness is not specified in the code description (i.e., we do not know the condition has lasted 12 months or longer) also are considered not chronic.